These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 39279704)

  • 1. COL12A1 Promotes Osteosarcoma Progression via the FAK/PI3K/AKT/mTOR Pathway.
    Zhang YP; Wang HX; Gao ZC; Xu LZ; Fu Y
    Curr Mol Med; 2024 Sep; ():. PubMed ID: 39279704
    [TBL] [Abstract][Full Text] [Related]  

  • 2. AIM2 inhibits the proliferation, invasion and migration, and promotes the apoptosis of osteosarcoma cells by inactivating the PI3K/AKT/mTOR signaling pathway.
    Zheng J; Liu C; Shi J; Wen K; Wang X
    Mol Med Rep; 2022 Feb; 25(2):. PubMed ID: 34913077
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MicroRNA‑22 mediates the cisplatin resistance of osteosarcoma cells by inhibiting autophagy via the PI3K/Akt/mTOR pathway.
    Meng CY; Zhao ZQ; Bai R; Zhao W; Wang YX; Xue HQ; Sun L; Sun C; Feng W; Guo SB
    Oncol Rep; 2020 Apr; 43(4):1169-1186. PubMed ID: 32323781
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SULF1 regulates malignant progression of colorectal cancer by modulating ARSH via FAK/PI3K/AKT/mTOR signaling.
    Zhu W; Wu C; Liu Z; Zhao S; Cheng X; Huang J
    Cancer Cell Int; 2024 Jun; 24(1):201. PubMed ID: 38844922
    [TBL] [Abstract][Full Text] [Related]  

  • 5. KIFC3 Promotes Proliferation, Migration, and Invasion in Colorectal Cancer
    Liao H; Zhang L; Lu S; Li W; Dong W
    Front Genet; 2022; 13():848926. PubMed ID: 35812733
    [No Abstract]   [Full Text] [Related]  

  • 6. RILP inhibits tumor progression in osteosarcoma via Grb10-mediated inhibition of the PI3K/AKT/mTOR pathway.
    Wei Z; Xia K; Zheng D; Gong C; Guo W
    Mol Med; 2023 Oct; 29(1):133. PubMed ID: 37789274
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PLEK2 promotes osteosarcoma tumorigenesis and metastasis by activating the PI3K/AKT signaling pathway.
    Liu Y; Yang S; Wang F; Zhou Z; Xu W; Xie J; Qiao L; Gu Y
    Oncol Lett; 2021 Jul; 22(1):534. PubMed ID: 34084215
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MTHFD1L as a folate cycle enzyme correlates with prognostic outcome and its knockdown impairs cell invasive behaviors in osteosarcoma via mediating the AKT/mTOR pathway.
    Wang L; Yang Y; Wang XM; Wang CQ; Zhang YM; Li BL
    J Recept Signal Transduct Res; 2020 Dec; 40(6):584-590. PubMed ID: 32456526
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ZIP10 drives osteosarcoma proliferation and chemoresistance through ITGA10-mediated activation of the PI3K/AKT pathway.
    Li H; Shen X; Ma M; Liu W; Yang W; Wang P; Cai Z; Mi R; Lu Y; Zhuang J; Jiang Y; Song Y; Wu Y; Shen H
    J Exp Clin Cancer Res; 2021 Oct; 40(1):340. PubMed ID: 34706747
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MiR-1224-5p Activates Autophagy, Cell Invasion and Inhibits Epithelial-to-Mesenchymal Transition in Osteosarcoma Cells by Directly Targeting PLK1 Through PI3K/AKT/mTOR Signaling Pathway.
    Jin B; Jin D; Zhuo Z; Zhang B; Chen K
    Onco Targets Ther; 2020; 13():11807-11818. PubMed ID: 33235467
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Actin-Like Protein 8 Promotes the Progression of Triple-Negative Breast Cancer via Activating PI3K/AKT/mTOR Pathway.
    Fan S; Yan S; Yang Y; Shang J; Hao M
    Onco Targets Ther; 2021; 14():2463-2473. PubMed ID: 33883901
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long Non-Coding RNA XLOC_006753 Promotes the Development of Multidrug Resistance in Gastric Cancer Cells Through the PI3K/AKT/mTOR Signaling Pathway.
    Zeng L; Liao Q; Zou Z; Wen Y; Wang J; Liu C; He Q; Weng N; Zeng J; Tang H; Fang R; Lei Z; Tang Z; Yang X; Cui S
    Cell Physiol Biochem; 2018; 51(3):1221-1236. PubMed ID: 30481766
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanism of miR-122-5p regulating the activation of PI3K-Akt-mTOR signaling pathway on the cell proliferation and apoptosis of osteosarcoma cells through targeting TP53 gene.
    Li KW; Wang SH; Wei X; Hou YZ; Li ZH
    Eur Rev Med Pharmacol Sci; 2020 Dec; 24(24):12655-12666. PubMed ID: 33378012
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-tumor efficacy of phellamurin in osteosarcoma cells: Involvement of the PI3K/AKT/mTOR pathway.
    Zhang H; Jiang H; Zhang H; Liu J; Hu X; Chen L
    Eur J Pharmacol; 2019 Sep; 858():172477. PubMed ID: 31228450
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diallyl trisulfide inhibits osteosarcoma 143B cell migration, invasion and EMT by inducing autophagy.
    Liu X; Wang N; He Z; Chen C; Ma J; Liu X; Deng S; Xie L
    Heliyon; 2024 Mar; 10(5):e26681. PubMed ID: 38434350
    [TBL] [Abstract][Full Text] [Related]  

  • 16. GCNT3 Promotes Hepatocellular Carcinoma Progression and EMT by Activating the PI3K/AKT Pathway.
    Wang Y; Fang X; Xie H; Wang X
    Biochem Genet; 2024 May; ():. PubMed ID: 38789846
    [TBL] [Abstract][Full Text] [Related]  

  • 17. UBE2S promotes the development of ovarian cancer by promoting PI3K/AKT/mTOR signaling pathway to regulate cell cycle and apoptosis.
    Zhang M; Liu Y; Yin Y; Sun Z; Wang Y; Zhang Z; Li F; Chen X
    Mol Med; 2022 Jun; 28(1):62. PubMed ID: 35658829
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cucurbitacin E inhibits osteosarcoma cells proliferation and invasion through attenuation of PI3K/AKT/mTOR signalling pathway.
    Wang Y; Xu S; Wu Y; Zhang J
    Biosci Rep; 2016 Dec; 36(6):. PubMed ID: 27653525
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting the PI3K/AKT/mTOR pathway offer a promising therapeutic strategy for cholangiocarcinoma patients with high doublecortin-like kinase 1 expression.
    Liang Z; Ge Y; Li J; Bai Y; Xiao Z; Yan R; An G; Zhang D
    J Cancer Res Clin Oncol; 2024 Jul; 150(7):342. PubMed ID: 38980538
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diosgenin Glucoside Inhibits the Progression of Osteosarcoma MG-63 by Regulating the PI3K/AKT/mTOR Pathway.
    Ruan S; Gu L; Wang Y; Huang X; Cao H
    Anticancer Agents Med Chem; 2023; 23(14):1670-1677. PubMed ID: 37078348
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.